Advances in Frontline Therapy for CLL

The use of molecular immune signatures for frontline treatment selection in advanced-stage FLПодробнее

Updates in CLL - 2023 Best of Hematology ConferenceПодробнее

Unmet needs in PTCL: improving frontline therapy and personalizing treatmentПодробнее

Ibrutinib and Venetoclax as Frontline Therapy For CLLПодробнее

Part 4- Real world experience with Acalabrutinib in management Treatment naïve CLL- Dr. John M PagelПодробнее

Challenges of selecting frontline therapy in CLLПодробнее

CLL14: feasibility of fixed-duration frontline therapy in CLLПодробнее

The evolution of frontline treatment for CLL: from chemoimmunotherapy to targeted agentsПодробнее

Advances in Treating CLLПодробнее

Ian W Flinn, ASCO 2018 – Recent advances in relapsed/refractory CLL, DLBCL & follicular lymphomaПодробнее

Advances in Frontline Therapy for EGFR+ NSCLCПодробнее

Debate: Is Maintenance Therapy of value following frontline treatment for advanced DLBCL - NoПодробнее

Frontline Therapy for Advanced Follicular LymphomaПодробнее

CLL Live 2015 - Dr. Nicole Lamanna, 'When and How to Treat'Подробнее

Role of chemotherapy in CLL managementПодробнее

Novel Frontline Combinations With Ibrutinib in CLLПодробнее

Selecting Frontline Therapy for CLLПодробнее

Maintenance and Frontline Therapy in CLLПодробнее